Samuel E DePrimo
Overview
Explore the profile of Samuel E DePrimo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dudink K, Bouwman K, Chen Y, DePrimo S, Munoz-Elias E, Aarts P, et al.
Br J Dermatol
. 2023 Feb;
188(5):601-609.
PMID: 36811949
Background: The effectiveness of available biologics for the treatment of hidradenitis suppurativa (HS) is limited. Additional therapeutic options are needed. Objectives: To investigate the efficacy and mode of action of...
2.
Boyle D, DePrimo S, Calderon C, Chen D, Dunford P, Barchuk W, et al.
Inflamm Res
. 2019 Feb;
68(4):261-274.
PMID: 30739130
Objective/design: In a double-blind, placebo-controlled, multiple-dose study, we assessed the molecular mechanism of action of the selective histamine-4-receptor antagonist toreforant. Patients/treatment: Patients with active rheumatoid arthritis (RA) despite methotrexate were...
3.
Loesche M, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Callis Duffin K, et al.
J Invest Dermatol
. 2018 Mar;
138(9):1973-1981.
PMID: 29559344
Plaque psoriasis, a chronic inflammatory disease primarily affecting the skin, is thought to have a multifactorial etiology, including innate immune system dysregulation, environmental triggers, and genetic susceptibility. We sought to...
4.
Harmon C, DePrimo S, Figlin R, Hudes G, Hutson T, Michaelson M, et al.
Cancer Chemother Pharmacol
. 2013 Nov;
73(1):151-61.
PMID: 24220935
Purpose: We investigated potential biomarkers of efficacy in a phase III trial of sunitinib versus interferon-alpha (IFN-α), first-line in metastatic renal cell carcinoma (mRCC), by analyzing plasma levels of vascular...
5.
Keyvanjah K, DePrimo S, Harmon C, Huang X, Kern K, Carley W
J Transl Med
. 2012 Aug;
10:165.
PMID: 22897944
Background: Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and stem cell factor receptor (KIT). The ability of soluble (s)KIT, VEGF-A, sVEGFR-2, and sVEGFR-3 to predict...
6.
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al.
J Transl Med
. 2011 Jul;
9:120.
PMID: 21787417
Background: Several proteins that promote angiogenesis are overexpressed in hepatocellular carcinoma (HCC) and have been implicated in disease pathogenesis. Sunitinib has antiangiogenic activity and is an oral multitargeted inhibitor of...
7.
LoRusso P, Krishnamurthi S, Rinehart J, Nabell L, Malburg L, Chapman P, et al.
Clin Cancer Res
. 2010 Mar;
16(6):1924-37.
PMID: 20215549
Purpose: To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901, a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor in advanced cancer patients. Experimental Design: Sixty-six...
8.
DePrimo S, Huang X, Blackstein M, Garrett C, Harmon C, Schoffski P, et al.
Clin Cancer Res
. 2009 Sep;
15(18):5869-77.
PMID: 19737953
Purpose: To evaluate changes in circulating levels of soluble KIT (sKIT) extracellular domain as a potential biomarker for clinical outcome in gastrointestinal stromal tumor patients treated with the multitargeted tyrosine...
9.
Rini B, Michaelson M, Rosenberg J, Bukowski R, Sosman J, Stadler W, et al.
J Clin Oncol
. 2008 Aug;
26(22):3743-8.
PMID: 18669461
Purpose: To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response. Patients And Methods: Patients with mRCC...
10.
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al.
J Clin Oncol
. 2008 Mar;
26(11):1810-6.
PMID: 18347007
Purpose: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor....